Zika P1 just started. Checked,
VGX-3100 P3 will be next. Then the VGX-3112 combo study w/ MedImmu. Then .....
Lot of good news are coming. The stock could hit $15-$17 by end of 2016 year, imo
+ Prostate cancer: tumor clearance is 70% (7 of 10) in mice study vs. control (0 of 10)
+ Dengue: 100% (10 of 10) vs. control (0 of 10)
Darpa awards INO w/ $57M grant to advance dMAb application and develop products for Ebola, influenza A and B, antibiotic resistant bacteria
VGX-3112, H&N SCCa P1/2a: Active, but completed recruiting. Last updated in Jun, 16. Data s/b in Aug/Sep
INO-5150: P1 prostate cancer. Active, but completed recruiting. Last updated in Jun, 16. Interim data s/b in Sep/Oct.
INO-1400: P1 Interim data s/b in any day now.
VGX-3100: P3 start in any day now
This is just my wild theory so that current INO's technologies can be moved faster under Big Pharm house and Dr Kim can enjoy his science study at whatever speed he desired.
If this happens, it will be a huge benefit to All
Senate fails to approval the Zika funding yesterday. They're now in recess period and will resume the talk after Labor day. No funding news till then, imo
INO needs to announce the P3 study soon to stop the bleeding
Com'on INO, move the P1 study as soon as possible
Everything should be ready (to proceed to P3 study), including the approval from both FDA and EMA
Not sure what's holding up?
My best guess that the next news will be the report of interim data of INO-1400...Last updated on Jun-16, looked like they have the data in hand..
Responsible Party: Inovio Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02327468 History of Changes
Other Study ID Numbers: UPCC 22913
Study First Received: December 23, 2014
Last Updated: June 16, 2016
Follow Juno news last week, CYTR stock down hard after hour Monday after late stage drug fails to expectation.
Can INO prove to be the best safety and efficacy?